Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-101 (VISTA)
    • SNS-401-NG
    • SNS-VSIG4
    • Presentations
  • Platform
    • TMAb Platform
    • ImmunoPhage Platform
      • Therapeutic cocktails
      • Phortress
      • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact
  • About
  • Pipeline
    • Overview
    • SNS-101 (VISTA)
    • SNS-401-NG
    • SNS-VSIG4
    • Presentations
  • Platform
    • TMAb Platform
    • ImmunoPhage Platform
      • Therapeutic cocktails
      • Phortress
      • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Daily Archives: November 13, 2021

SITC 2021: Preclinical data for SNS-101

PresentationBy spb_devNovember 13, 2021
…
© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top